Skip to Content

Duraclon (clonidine) Disease Interactions

There are 5 disease interactions with Duraclon (clonidine):

Moderate

Alpha-2 Agonists (Central) (Includes Duraclon) ↔ Bradyarrhythmia

Moderate Potential Hazard, High plausibility

Applies to: Heart Block, Sinus Node Dysfunction

Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system. Heart rate is decreased, which may lead to or exacerbate sinus bradycardia and atrioventricular block. Therapy with central alpha-2 adrenoreceptor agonists should be administered cautiously in patients with conduction disturbances such as sinus node dysfunction or AV nodal disease.

References

  1. "Product Information. Catapres (clonidine)." Boehringer-Ingelheim, Ridgefield, CT.
  2. van Zwieten PA, Thoolen MJ, Timmermans PB "The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine." Hypertension 6 (1984): 28-33
  3. "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  4. Golusinski LL, Blount BW "Clonidine-induced bradycardia." J Fam Pract 41 (1995): 399-401
  5. Schwartz E, Friedman E, Mouallem M, Farfel Z "Sinus arrest associated with clonidine therapy." Clin Cardiol 11 (1988): 53-4
  6. "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  7. Byrd BF, Collins HW, Primm RK "Risk factors for severe bradycardia during oral clonidine therapy for hypertension." Arch Intern Med 148 (1988): 729-33
View all 7 references
Moderate

Alpha-2 Agonists (Central) (Includes Duraclon) ↔ Depression

Moderate Potential Hazard, Moderate plausibility

Applies to: Depression

Central alpha-2 adrenoreceptor agonists may occasionally cause mental depression and should be used cautiously in patients with a history of depression.

References

  1. Kostis JB, Rosen RC, Holzer BC, et al "CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males." Psychopharmacology (Berl) 102 (1990): 163-70
  2. Prasad A, Shotliff K "Depression and chronic clonidine therapy." Postgrad Med J 69 (1993): 327-8
  3. "Product Information. Catapres (clonidine)." Boehringer-Ingelheim, Ridgefield, CT.
  4. "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  5. "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
View all 5 references
Moderate

Alpha-2 Agonists (Central) (Includes Duraclon) ↔ Hypotension

Moderate Potential Hazard, High plausibility

Applies to: Hypotension, Ischemic Heart Disease, Peripheral Arterial Disease, Cerebrovascular Insufficiency

Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure. Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud's syndrome), cerebrovascular disease, or recent myocardial infarction.

References

  1. Greene CS, Gretler DD, Cervenka K, et al "Cerebral blood flow during the acute therapy of severe hypertension with oral clonidine." Am J Emerg Med 8 (1990): 293-6
  2. Fruncillo RJ, Gibbons WJ, Vlasses PH, Ferguson RK "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274
  3. Bauer JH "Effects of guanabenz therapy on renal function and body fluid composition." Arch Intern Med 143 (1983): 1163-7
  4. "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  5. Anavekar SN, Jarrott B, Toscano M, Louis WJ "Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects." Eur J Clin Pharmacol 23 (1982): 1-5
  6. Mosley C, O'Connor DT, Taylor A, et al "Comparative effects of antihypertensive therapy with guanabenz and propranolol on renal vascular resistance and left ventricular mass." J Cardiovasc Pharmacol 6 (1984): s757-61
  7. van Zwieten PA, Thoolen MJ, Timmermans PB "The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine." Hypertension 6 (1984): 28-33
  8. "Product Information. Catapres (clonidine)." Boehringer-Ingelheim, Ridgefield, CT.
  9. Dziedzic SW, Elijovich F, Felton K, et al "Effect of guanabenz on blood pressure responses to posture and exercise." Clin Pharmacol Ther 33 (1983): 151-5
  10. "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  11. Given BD, Taylor T, Lilly LS, Dzau VJ "Symptomatic hypotension following the clonidine suppression test for pheochromocytoma." Arch Intern Med 143 (1983): 2195-6
  12. Bosanac P, Dubb J, Walker B, et al "Renal effects of guanabenz: a new antihypertensive." J Clin Pharmacol Nov-Dec (1976): 631-6
View all 12 references
Moderate

Clonidine (Includes Duraclon) ↔ Renal Dysfunction

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Clonidine is primarily eliminated unchanged by the kidney. The serum concentrations and half-life of clonidine may be increased in patients with impaired renal function, so patients may benefit from a lower initial dose. Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment. Only a minimal amount of clonidine is removed during routine hemodialysis, and there is no need to give supplemental clonidine following dialysis.

References

  1. Lowenthal DT, Affrime MB, Meyer A, et al "Pharmacokinetics and pharmacodynamics of clonidine in varying states of renal function." Chest 83 (1983): 386-90
  2. "Product Information. Catapres (clonidine)." Boehringer-Ingelheim, Ridgefield, CT.
  3. Hulter HN, Licht JH, Ilnicki LP, Singh S "Clinical efficacy and pharmacokinetics of clonidine in hemodialysis and renal insufficiency." J Lab Clin Med 94 (1979): 223-31
Moderate

Clonidine (Includes Duraclon) ↔ Sedatives/Alcohol

Moderate Potential Hazard, Moderate plausibility

Applies to: Alcoholism

Patients may experience a sedative effect, dizziness, or accommodation disorder with the use of clonidine. Patients should be cautioned about engaging in activities such as driving a vehicle or operating machinery. The sedative effect may be increased with the concomitant use of alcohol or other sedating drugs.

Duraclon (clonidine) drug Interactions

There are 746 drug interactions with Duraclon (clonidine)

Duraclon (clonidine) alcohol/food Interactions

There is 1 alcohol/food interaction with Duraclon (clonidine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide